| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Triamcinolone acetonide (Acetospan; Adcortyl A; AllerNaze; Kenalone; Nasacort; Aristocort; Aristoderm. Aristogel) is a potent and synthetic glucocorticoid with improved anti-inflammatory activities.
| ln Vitro |
As the concentration rises, triamcinolone acetonide (0.05-3 mg/mL, 48-60 h) decreases BRECs' capacity to proliferate [1]. In a concentration-dependent manner, triamcinolone acetonide (0.04-5 mg/mL, 24 h) decreases the viability of both normal and osteoarthritic (OA) chondrocytes [2]. The degree of cartilage structural degradation, chondrocyte loss and colony formation, and proteoglycan loss in OA cartilage are all made worse by triamcinolone acetonide (0.04-5 mg/mL, 24 h) [2]. Strongly inducing monocyte differentiation toward M2 and anti-inflammatory macrophage phenotypes is triamcinolone acetonide (100 nM, 7 days) [3].
|
|---|---|
| ln Vivo |
In rats with osteoarthritis, intraperitoneal injection of 1.43 mg/mL triamcinolone acetonide once a week for 6–12 weeks totally stops the development of osteophytes and improves FRβ-related macrophage activation [3].
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: Chondrocyte Tested Concentrations: 0.04, 0.08, 0.16, 0.31, 0.63, 1.25, 2.5, and 5 mg/ml Incubation Duration: 24 h Experimental Results: decreased cell viability with the value of IC50 was 2.23 mg/ mL in normal chondrocytes and 1.14 mg/mL in OA chondrocytes. |
| Animal Protocol |
Animal/Disease Models: Severe OA rat model [3]
Doses: 1.43 mg/mL Route of Administration: intraperitoneal (ip)injection Experimental Results: diminished body weight during OA induction. demonstrated more macrophage activation and minimal or no osteophyte formation when injected knee joints. |
| References | |
| Additional Infomation |
Triamcinolone acetonide is a synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections. It has a role as an anti-inflammatory drug and an anti-allergic agent. It is an 11beta-hydroxy steroid, a 20-oxo steroid, a 21-hydroxy steroid, a 3-oxo-Delta(4) steroid, a glucocorticoid, a cyclic ketal, a fluorinated steroid and a primary alpha-hydroxy ketone. It is functionally related to a triamcinolone. It derives from a hydride of a pregnane.
Triamcinolone acetonide is a Corticosteroid. The mechanism of action of triamcinolone acetonide is as a Corticosteroid Hormone Receptor Agonist. Triamcinolone Acetonide is the acetonide salt form of triamcinolone, a synthetic glucocorticosteroid with immunosuppressive and anti-inflammatory activity. Triamcinolone acetonide binds to specific cytosolic glucocorticoid receptors and subsequently interacts with glucocorticoid receptor response element on DNA and alters gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished. An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions. See also: Triamcinolone (has active moiety); Triamcinolone Hexacetonide (active moiety of); Triamcinolone Benetonide (is active moiety of) ... View More ... Drug Indication Visualisation during vitrectomy |
| Molecular Formula |
C24H31FO6
|
|
|---|---|---|
| Molecular Weight |
434.5
|
|
| Exact Mass |
434.21
|
|
| CAS # |
76-25-5
|
|
| Related CAS # |
Triamcinolone acetonide (Standard);76-25-5;Triamcinolone acetonide-d7;Triamcinolone acetonide-d7-1;Triamcinolone acetonide-d6;352431-33-5
|
|
| PubChem CID |
6436
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Boiling Point |
576.9±50.0 °C at 760 mmHg
|
|
| Melting Point |
274-278ºC (dec.)
|
|
| Flash Point |
302.7±30.1 °C
|
|
| Vapour Pressure |
0.0±3.6 mmHg at 25°C
|
|
| Index of Refraction |
1.589
|
|
| LogP |
2.5
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
7
|
|
| Rotatable Bond Count |
2
|
|
| Heavy Atom Count |
31
|
|
| Complexity |
925
|
|
| Defined Atom Stereocenter Count |
8
|
|
| SMILES |
C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@@]53C)F)O
|
|
| InChi Key |
YNDXUCZADRHECN-JNQJZLCISA-N
|
|
| InChi Code |
InChI=1S/C24H31FO6/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,25)17(28)11-22(16,4)24(19,31-20)18(29)12-26/h7-9,15-17,19,26,28H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1
|
|
| Chemical Name |
(6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-6b-fluoro-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2,1:4,5]indeno[1,2-d][1,3]dioxol-4-one
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.79 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3015 mL | 11.5075 mL | 23.0150 mL | |
| 5 mM | 0.4603 mL | 2.3015 mL | 4.6030 mL | |
| 10 mM | 0.2301 mL | 1.1507 mL | 2.3015 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Effectiveness of Periocular Drug Injection in CATaract Surgery
CTID: NCT05158699
Phase: Phase 3 Status: Terminated
Date: 2024-11-04
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA